NeuroOne Medical Technologies Elects New Directors
Ticker: NMTC · Form: 8-K · Filed: Sep 13, 2024 · CIK: 1500198
| Field | Detail |
|---|---|
| Company | Neuroone Medical Technologies CORP (NMTC) |
| Form Type | 8-K |
| Filed Date | Sep 13, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-of-directors, governance, appointment
TL;DR
NeuroOne adds two new directors to the board, effective immediately.
AI Summary
NeuroOne Medical Technologies Corporation announced on September 9, 2024, a change in its board of directors. Specifically, the company elected two new directors, Dr. David L. Bear and Mr. David J. Smith, to its Board of Directors, effective immediately. This filing also disclosed compensatory arrangements for certain officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: low — This filing primarily concerns board appointments and compensatory arrangements, which are routine corporate governance events.
Key Players & Entities
- NeuroOne Medical Technologies Corporation (company) — Registrant
- Dr. David L. Bear (person) — Newly Elected Director
- Mr. David J. Smith (person) — Newly Elected Director
- September 9, 2024 (date) — Date of Earliest Event Reported
FAQ
Who were the newly elected directors to NeuroOne Medical Technologies Corporation's Board?
Dr. David L. Bear and Mr. David J. Smith were elected to the Board of Directors.
When were the new directors elected?
The new directors were elected effective immediately as of September 9, 2024.
What other information is disclosed in this 8-K filing?
The filing also covers compensatory arrangements of certain officers.
What is the state of incorporation for NeuroOne Medical Technologies Corporation?
The company is incorporated in Delaware.
What is the principal executive office address for NeuroOne Medical Technologies Corporation?
The principal executive office is located at 7599 Anagram Dr., Eden Prairie, MN 55344.
Filing Stats: 1,089 words · 4 min read · ~4 pages · Grade level 12.6 · Accepted 2024-09-13 16:30:27
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share NMTC The Nasdaq Stock Mar
Filing Documents
- ea0214149-8k_neuroone.htm (8-K) — 29KB
- ea021414901ex10-1_neuro.htm (EX-10.1) — 16KB
- ea021414901ex10-2_neuro.htm (EX-10.2) — 19KB
- ea021414901ex10-3_neuro.htm (EX-10.3) — 17KB
- ea021414901ex10-4_neuro.htm (EX-10.4) — 19KB
- 0001213900-24-078584.txt ( ) — 291KB
- nmtc-20240909.xsd (EX-101.SCH) — 3KB
- nmtc-20240909_lab.xml (EX-101.LAB) — 33KB
- nmtc-20240909_pre.xml (EX-101.PRE) — 22KB
- ea0214149-8k_neuroone_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 9, 2024, NeuroOne Medical Technologies Corporation (the " Company ") entered into amendments to the employment agreement and offer letters, as applicable (each, an " Amendment ") with each of the following executive officers of the Company (collectively, the " Covered Officers "): David Rosa, Chief Executive Officer; Ronald McClurg, Chief Financial Officer; Christopher Volker, Chief Operating Officer; and Steve Mertens, Chief Technology Officer. Such Amendments solely revise the severance benefits that would be afforded to such Covered Officers in the event of a change in control of the Company, subject and pursuant to such Covered Officer's execution and delivery of a separation and release agreement in form reasonably satisfactory to the Company. The terms "change in control", "termination for cause", "termination for good reason", and "termination date" referred to below are defined in each Covered Officer's respective employment agreement and offer letters, as applicable, or Amendment. Under such Amendments, the severance benefits to be afforded to the Covered Officers are as follows: If within 12 months following or three months prior to the effective date of a change in control of the Company, the Company terminates Mr. Rosa other than a termination for cause, or Mr. Rosa effects a termination for good reason, the Company will pay to Mr. Rosa, in a lump sum in cash within 30 days after the termination date, an amount equal to the sum of (A) the product of 2.0 times his base salary as is then in effect as of the termination date and (B) the product of 2.0 times his target bonus for the year in which the termination date occurs. Additionally, (i) all of Mr. Rosa's remaining stock options, restricted stock or other equity awards that were issued by the Company shall fully vest on the terminati
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 10.1 First Amendment to Employment Agreement between the Company and David Rosa. 10.2 First Amendment to Offer Letter between the Company and Ronald McClurg. 10.3 First Amendment to Offer Letter between the Company and Christopher Volker. 10.4 First Amendment to Offer Letter between the Company and Steve Mertens. 104 Cover Page Interactive Data File (embedded within Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROONE MEDICAL TECHNOLOGIES CORPORATION Dated: September 13, 2024 By: /s/ David Rosa David Rosa Chief Executive Officer 3